Research Article

Transcatheter arterial chemoembolization combined with molecular targeted therapy for a patient with hepatocellular carcinoma with intrahepatic metastasis and main portal vein tumor thrombus: A case report and literature review

Yu Zhong Wen, Shi Jie Dai, Su Fen Cheng, Jun Shi and Jun Hua Ai*

Published: 06/02/2020 | Volume 4 - Issue 1 | Pages: 036-038

Abstract

Hepatocellular carcinoma (HCC) is characterized by high morbidity, high recurrence, and high mortality rates. In China, the morbidity of HCC is fifth among all malignant tumors and HCC is the third most common cause of cancer-related deaths. Most HCC patients also have liver cirrhosis. Surgery is the sole curative method for HCC; however, many patients are diagnosed with HCC during its advanced stages so radical resection can no longer be performed. Therefore, the proportion of patients who undergo radical hepatectomy is less than 30%. Patients with mildly advanced HCC cannot undergo hepatectomy and thus transcatheter arterial chemoembolization (TACE) and/or biological targeted therapy are alternative options. However, data on the effects of TACE therapy or biological targeted therapy are limited. Therefore, an investigation of multimodal and individualized treatments is critical to ensure the best treatment. In June 2018, we treated an advanced HCC patient with multiple metastases and right portal vein tumor thrombus. The patient exhibited partial remission after undergoing treatment with TACE and crizotinib capsules for 1 month. The case and a literature review are reported here.

Read Full Article HTML DOI: 10.29328/journal.acgh.1001020 Cite this Article

References

  1. Public Health and Family Planning Commission in the People’s Republic of China. Specification for diagnosis and treatment of primary liver cancer. Chinese Journal of Practical Surgery. 2017; 37: 114-126.
  2. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011; 18: 413–420. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20839057
  3. Niu ZJ, Ma YL, Kang P, Ou SQ, Meng ZB, et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol. 2012; 29: 2992–2997. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22200992
  4. Sur BW, Sharma A. Transarterial Chemoembolization for Hepatocellular Carcinoma. J Radiol Nurs. 2018; 37: 107-111.
  5. Tian M, Zhang X, Huang G, Fan W, Li J, et al. Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization. Abdominal Radiology. 2019; 44: 3304-3311. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31250181
  6. Yuan J, Yin X, Tang B, Ma H, Zhang L, et al. Transarterial Chemoembolization(TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. BioMed Res Int. 2019; 2019: 2141859. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699376/
  7. Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, et al. Sorafenib With or Without Concurrent Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma: The Phase III STAH Trial. J Hepatol. 2019; 70: 684-691. PubMed: https://pubmed.ncbi.nlm.nih.gov/30529387/